XOMA Royalty (XOMA) Projected to Post Earnings on Tuesday

XOMA Royalty (NASDAQ:XOMA) is expected to post its Q1 2026 results before the market opens on Tuesday, May 12th. Analysts expect XOMA Royalty to post earnings of $0.1285 per share and revenue of $13.8730 million for the quarter. Individuals can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Friday, May 15, 2026 at 9:30 AM ET.

XOMA Royalty (NASDAQ:XOMA) last announced its quarterly earnings results on Wednesday, March 18th. The biotechnology company reported $0.12 earnings per share for the quarter, beating the consensus estimate of ($0.04) by $0.16. The company had revenue of $13.76 million during the quarter, compared to analysts’ expectations of $11.13 million. XOMA Royalty had a return on equity of 10.32% and a net margin of 45.75%. On average, analysts expect XOMA Royalty to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

XOMA Royalty Stock Performance

XOMA stock traded up $0.17 during trading on Tuesday, hitting $41.21. 58,603 shares of the company traded hands, compared to its average volume of 373,935. The stock’s 50-day simple moving average is $32.10 and its 200 day simple moving average is $30.16. The company has a debt-to-equity ratio of 1.15, a current ratio of 3.37 and a quick ratio of 3.37. The company has a market cap of $491.22 million, a PE ratio of 28.23 and a beta of 0.90. XOMA Royalty has a 1 year low of $22.29 and a 1 year high of $42.81.

Analyst Ratings Changes

Several research analysts recently weighed in on XOMA shares. Lucid Cap Mkts cut XOMA Royalty from a “strong-buy” rating to a “hold” rating in a research report on Monday, April 27th. Leerink Partners reiterated an “outperform” rating on shares of XOMA Royalty in a research report on Tuesday, February 24th. TD Cowen upgraded XOMA Royalty to a “hold” rating in a research report on Friday, February 13th. HC Wainwright cut XOMA Royalty from a “buy” rating to a “neutral” rating and set a $39.00 price target for the company. in a research report on Thursday, April 30th. Finally, Zacks Research upgraded XOMA Royalty from a “strong sell” rating to a “hold” rating in a research report on Wednesday, April 8th. Two equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $53.75.

Institutional Trading of XOMA Royalty

A number of institutional investors and hedge funds have recently made changes to their positions in XOMA. Opaleye Management Inc. increased its position in shares of XOMA Royalty by 14.7% in the fourth quarter. Opaleye Management Inc. now owns 292,590 shares of the biotechnology company’s stock valued at $7,780,000 after buying an additional 37,503 shares in the last quarter. Woodline Partners LP increased its position in shares of XOMA Royalty by 16.5% in the third quarter. Woodline Partners LP now owns 209,945 shares of the biotechnology company’s stock valued at $8,091,000 after buying an additional 29,715 shares in the last quarter. Vanguard Group Inc. increased its position in shares of XOMA Royalty by 4.6% in the third quarter. Vanguard Group Inc. now owns 668,111 shares of the biotechnology company’s stock valued at $25,749,000 after buying an additional 29,298 shares in the last quarter. Occudo Quantitative Strategies LP purchased a new stake in shares of XOMA Royalty in the second quarter valued at approximately $527,000. Finally, Geode Capital Management LLC increased its position in shares of XOMA Royalty by 9.1% in the second quarter. Geode Capital Management LLC now owns 203,601 shares of the biotechnology company’s stock valued at $5,132,000 after buying an additional 16,929 shares in the last quarter. 95.92% of the stock is currently owned by hedge funds and other institutional investors.

About XOMA Royalty

XOMA Royalty (NASDAQ: XOMA) is a specialty healthcare royalty company that acquires and manages royalty interests in small-molecule and biologic drugs. The company’s business model centers on purchasing royalty streams on marketed or near-market pharmaceutical products, providing capital to developers in exchange for a share of future net sales. By focusing on late-stage assets with established clinical and commercial profiles, XOMA Royalty aims to generate predictable, long-term cash flows for its shareholders.

The company’s investment portfolio spans a range of therapeutic areas, including oncology, immunology and rare diseases.